207 related articles for article (PubMed ID: 21818552)
1. NAD(P)H: quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions.
Zhu H; Li Y
Cardiovasc Toxicol; 2012 Mar; 12(1):39-45. PubMed ID: 21818552
[TBL] [Abstract][Full Text] [Related]
2. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
3. No associations between Parkinson's disease and polymorphisms of the quinone oxidoreductase (NQO1, NQO2) genes.
Okada S; Farin FM; Stapleton P; Viernes H; Quigley SD; Powers KM; Smith-Weller T; Franklin GM; Longstreth WT; Swanson PD; Checkoway H
Neurosci Lett; 2005 Mar; 375(3):178-80. PubMed ID: 15694256
[TBL] [Abstract][Full Text] [Related]
4. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.
Wu K; Knox R; Sun XZ; Joseph P; Jaiswal AK; Zhang D; Deng PS; Chen S
Arch Biochem Biophys; 1997 Nov; 347(2):221-8. PubMed ID: 9367528
[TBL] [Abstract][Full Text] [Related]
5. Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.
den Braver-Sewradj SP; den Braver MW; Toorneman RM; van Leeuwen S; Zhang Y; Dekker SJ; Vermeulen NPE; Commandeur JNM; Vos JC
Chem Res Toxicol; 2018 Feb; 31(2):116-126. PubMed ID: 29281794
[TBL] [Abstract][Full Text] [Related]
6. Role of Nad(P)h: quinone oxidoreductase in the regulation of intracellular redox state.
Mohora M
Rom J Intern Med; 2000-2001; 38-39():33-50. PubMed ID: 15529570
[TBL] [Abstract][Full Text] [Related]
7. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.
Siegel D; Gustafson DL; Dehn DL; Han JY; Boonchoong P; Berliner LJ; Ross D
Mol Pharmacol; 2004 May; 65(5):1238-47. PubMed ID: 15102952
[TBL] [Abstract][Full Text] [Related]
8. Roles of NAD(P)H:quinone Oxidoreductase 1 in Diverse Diseases.
Lee WS; Ham W; Kim J
Life (Basel); 2021 Nov; 11(12):. PubMed ID: 34947831
[TBL] [Abstract][Full Text] [Related]
9. Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides.
Kucera HR; Livingstone M; Moscoso CG; Gaikwad NW
Free Radic Res; 2013 Dec; 47(12):1016-26. PubMed ID: 24074361
[TBL] [Abstract][Full Text] [Related]
10. Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue.
Strassburg A; Strassburg CP; Manns MP; Tukey RH
Mol Pharmacol; 2002 Feb; 61(2):320-5. PubMed ID: 11809856
[TBL] [Abstract][Full Text] [Related]
11. Association analyses between polymorphisms of the phase II detoxification enzymes (GSTM1, NQO1, NQO2) and alcohol withdrawal symptoms.
Okubo T; Harada S; Higuchi S; Matsushita S
Alcohol Clin Exp Res; 2003 Aug; 27(8 Suppl):68S-71S. PubMed ID: 12960511
[TBL] [Abstract][Full Text] [Related]
12. Interactions of the antioxidant enzymes NAD(P)H: Quinone oxidoreductase 1 (NQO1) and NRH: Quinone oxidoreductase 2 (NQO2) with pharmacological agents, endogenous biochemicals and environmental contaminants.
Rashid MH; Babu D; Siraki AG
Chem Biol Interact; 2021 Aug; 345():109574. PubMed ID: 34228969
[TBL] [Abstract][Full Text] [Related]
13. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.
Knox RJ; Jenkins TC; Hobbs SM; Chen S; Melton RG; Burke PJ
Cancer Res; 2000 Aug; 60(15):4179-86. PubMed ID: 10945627
[TBL] [Abstract][Full Text] [Related]
14. The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger.
Zhu H; Jia Z; Mahaney JE; Ross D; Misra HP; Trush MA; Li Y
Cardiovasc Toxicol; 2007; 7(3):202-11. PubMed ID: 17901563
[TBL] [Abstract][Full Text] [Related]
15. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6.
Jaiswal AK; Burnett P; Adesnik M; McBride OW
Biochemistry; 1990 Feb; 29(7):1899-906. PubMed ID: 1691923
[TBL] [Abstract][Full Text] [Related]
16. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors.
Nioi P; Hayes JD
Mutat Res; 2004 Nov; 555(1-2):149-71. PubMed ID: 15476858
[TBL] [Abstract][Full Text] [Related]
17. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis.
Long DJ; Waikel RL; Wang XJ; Perlaky L; Roop DR; Jaiswal AK
Cancer Res; 2000 Nov; 60(21):5913-5. PubMed ID: 11085502
[TBL] [Abstract][Full Text] [Related]
18. Biological response of human diploid keratinocytes to quinone-producing compounds: role of NAD(P)H:quinone oxidoreductase 1.
Foppoli C; De Marco F; Blarzino C; Perluigi M; Cini C; Coccia R
Int J Biochem Cell Biol; 2005 Apr; 37(4):852-63. PubMed ID: 15694844
[TBL] [Abstract][Full Text] [Related]
19. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53.
Gong X; Kole L; Iskander K; Jaiswal AK
Cancer Res; 2007 Jun; 67(11):5380-8. PubMed ID: 17545619
[TBL] [Abstract][Full Text] [Related]
20. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.
Ross D; Kepa JK; Winski SL; Beall HD; Anwar A; Siegel D
Chem Biol Interact; 2000 Dec; 129(1-2):77-97. PubMed ID: 11154736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
